Sodium Glucose Cotransporter 2 Inhibitors Shown to Improve Heart Function in Heart Failure Patients

Strategic Insights -

A recent study published in the South Valley University - International Journal of Medical Sciences has found that sodium glucose cotransporter 2 inhibitors (SGLT2i) can significantly improve heart function in patients with heart failure and pulmonary hypertension, regardless of whether they have type 2 diabetes mellitus (DM). The study, which included 100 patients, demonstrated that SGLT2i had a greater impact on pulmonary artery pressure and right ventricular function compared to optimal medical treatment alone.

Key Takeaways:

  • The study investigated the effect of SGLT2i on pulmonary artery pressure, right ventricular function, and red blood cell distribution width (RDW) in heart failure patients with pulmonary hypertension and/or type 2 diabetes mellitus.
  • The researchers found that SGLT2i had a greater impact on pulmonary artery pressure and right ventricular function compared to optimal medical treatment alone.
  • The study included 100 patients (16 years and older) with heart failure and pulmonary hypertension, with or without type 2 diabetes mellitus.
  • The study concluded that SGLT2i is established as a treatment for heart failure patients, regardless of type 2 diabetes mellitus.
  • The study highlights the importance of SGLT2i in improving heart function in patients with heart failure and pulmonary hypertension.
  • The researchers suggest that SGLT2i may be used as a potential treatment for heart failure patients with pulmonary hypertension.

Statistics:

  • 100 patients were included in the study, with ages ranging from 16 years and older.
  • The study found that SGLT2i had a greater impact on pulmonary artery pressure and right ventricular function compared to optimal medical treatment alone.
  • 16 years was the minimum age of patients included in the study.
  • The study concluded that SGLT2i had a significant impact on PH and RV function compared to optimal medical treatment alone.

Sources:

  • SVU - International Journal of Medical Sciences, 2025,8(1):1196-1206.
  • South Valley University, Faculty of Medicine. A free version of this journal article is available at https://doi-org.sdpl.idm.oclc.org/https://doi.org/10.21608/svuijm.2025.346232.2056.